Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Ankle implant tracked for Long-Term success in arthritis patients

NCT ID NCT03247023

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 65 adults with ankle arthritis (from wear-and-tear, injury, or conditions like rheumatoid arthritis) who received the Cadence Total Ankle System implant. Researchers tracked how long the implant lasted without needing removal or revision, checking at 2, 5, and 10 years. The goal was to see if the device is safe and durable for long-term use.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Integra Cadence Total Ankle System (ankle replacement implant)
What this could lead to
If successful, this could confirm that the Cadence ankle implant is a safe and durable option for people with severe ankle arthritis, potentially improving mobility and reducing pain for years.
What could go wrong
This trial was terminated early and only enrolled 65 people, so results may be limited. As with any joint replacement, risks include implant loosening, infection, or need for revision surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

65 people

The number who actually took part.

Started

Sep 2017

Finished

Sep 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patient with ankle arthritis requiring total ankle replacement

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Subjects will be included if he/she: 1. Is \> 18 years of age. 2. Is skeletally mature. 3. Qualifies for primary TAR per the surgeon and has a diagnosis of one of the following: primary arthritis (e.g. degenerative disease), secondary arthritis (e.g. post-traumatic, avascular necrosis, if minimally 2/3 of the talus is preserved), or systemic arthritis of the ankle (e.g. rheumatoid arthritis, hemochromatosis). 4. Is suitable for TAR with CTAS per the study surgeon based on the product indication and having considered deformity, stability, bone quality, soft- tissue envelope, and neurovascular status. 5. Is willing and able to cooperate in the required post-operative therapy. 6. Is willing and able to complete scheduled follow-up visits, evaluations, and questionnaires as described in the Informed Consent or Information Letter and Data Transfer Authorization Form, as applicable. 7. Reads, understands and signs the Ethical Committee approved Informed Consent or Information Letter and Data Transfer Authorization Form, as applicable Exclusion Criteria: Subjects will be excluded from the study if he/she: 1. Is Morbidly Obese (defined by BMI \> 40 or BMI of 35 - 40 with significant medical problems caused by or made worse by their weight). 2. Is an active nicotine user (smoking, chewing, smokeless tobacco, patch) and unwilling to cease nicotine use within 1 month prior to surgery, and 2 months post-surgery. 3. Has one of the following conditions, which could compromise the affected limb: ankle arthrodesis with malleolar exeresis, severe neurological (Charcot's Arthropathy) or vascular disease, loss of musculature or neuromuscular compromise. 4. Has an active local/systemic infection that may affect the prosthetic joint or has a recent history of infection. 5. Continues on long-term medication, which may compromise bone stock (e.g. undergoing immunosuppressive therapy, long-term steroids) and is unable to cease medication usage from 3 weeks prior to surgery to 3 weeks post-surgery. 6. Has a condition that may impair proper wound healing (e.g., poor soft tissue envelope). 7. Had previous ankle surgery and/or injury that has adversely affected the anklebone stock. 8. Has had or is scheduled to have contralateral TAR surgery. 9. Is pregnant or plans to become pregnant during the follow up period. 10. Has a metabolic disorder or disease that may compromise bone quality (e.g. arthrogryposis etc.), physiological or anatomical anomalies, and/or malignancy/local bone tumors. 11. Has severe avascular necrosis of the talus/tibia. 12. Has inadequate neuromuscular status (e.g., prior paralysis, severe neuropathy). 13. Has a known sensitivity or allergic reaction to one or more of the implanted materials. 14. Is a poor candidate for general anesthesia. 15. Is a prisoner, mentally incompetent or unable to understand what participation in this study entails, a known alcohol or drug abuser, or anticipated to be non- compliant.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Degenerative arthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CHRU Tours

    Tours, 37044, France

  • Clinica Nostra Senhora del Remei

    Barcelona, 08024, Spain

  • Foot and Ankle Institute

    Woluwe-St-Lambert, B-1200, Belgium

  • North Cumbria University Hospitals

    Carlisle, CA2 7HY, United Kingdom

  • St. Michael's Hospital

    Toronto, M5C 1R6, Canada

  • Universitair Ziekenhuis Gent

    Ghent, 9000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.